Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag

Introduction: Parenteral prostanoids are the most potent therapies for pulmonary arterial hypertension (PAH) but are associated with complications and lifestyle limitations. Carefully selected stable patients may be considered for a transition from parenteral prostanoids to a more convenient oral r...

Full description

Bibliographic Details
Main Authors: Colin Hinkamp, Sonja Bartolome, Edward Mims, Kelly Chin, Trushil Shah
Format: Article
Language:English
Published: Karger Publishers 2022-10-01
Series:Biomedicine Hub
Subjects:
pulmonary arterial hypertension
pulmonary hypertension
prostacyclin
prostaglandins
six-minute walk distance
Online Access:https://www.karger.com/Article/FullText/526190

Internet

https://www.karger.com/Article/FullText/526190

Similar Items